ABEO - Abeona Therapeutics Inc

5.34
-0.050   -0.936%

Share volume: 597,632
Last Updated: 04-27-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$5.39
-0.05
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
57%
Profitability 53%
Dept financing 28%
Liquidity 75%
Performance 65%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.26%
1 Month
26.24%
3 Months
10.56%
6 Months
1.14%
1 Year
-0.19%
2 Year
55.23%
Key data
Stock price
$5.34
P/E Ratio 
N/A
DAY RANGE
$5.30 - $5.48
EPS 
$1.34
52 WEEK RANGE
$4.00 - $7.54
52 WEEK CHANGE
$0.75
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
57.049 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$780,523
AVERAGE 30 VOLUME 
$1,019,270
Company detail
CEO: Vishwas Seshadri
Region: US
Website: abeonatherapeutics.com
Employees: 90
IPO year: 1980
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Abeona Therapeutics Inc. develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A.

Recent news